Associates In Internal Medicine Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 320 E 3rd Ave, Tarentum, PA 15084 Phone: 724-224-0700 Fax: 724-224-0823 |
Lawrence Ferlan, Md Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 317 1st Ave, Tarentum, PA 15084 Phone: 724-226-2900 Fax: 724-226-3435 |
Digestive Disease Consultants Inc Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 301 First Avenue, Tarentum, PA 15084 Phone: 724-224-3113 Fax: 724-224-2447 |
Usha Sivakumar Md Llc Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 415 E 4th Ave, Suite# 3, Tarentum, PA 15084 Phone: 724-224-3530 Fax: 724-224-3531 |
Associates In Internal Medicine Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 320 E 3rd Ave, Tarentum, PA 15084 Phone: 724-224-0700 Fax: 724-224-0823 |
Associates In Internal Medicine Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 320 E 3rd Ave, Tarentum, PA 15084 Phone: 724-224-0700 Fax: 724-224-0823 |
News Archive
Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources.
NOD Pharmaceuticals Inc. announced the US Patent & Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or NOD technology.
With a multimillion-dollar electron microscope and computer programs that can pick out the shapes of structures only six atoms wide, Dr. Wah Chiu and his colleagues at Baylor College of Medicine in Houston are attempting to explain the intricate structures of viruses and proteins.
Advanced Cell Technology, Inc. a leader in the field of regenerative medicine, today announced treatment of the first patient in the third dosage cohort, and seventh patient overall, in its European Phase I clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
› Verified 9 days ago